Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study

Samantha Pozzi, Massimo Gentile, Stefano Sacchi, Raffaella Marcheselli, Alessandro Corso, Federica Cocito, Pellegrino Musto, Attilio Guarini, Carla Minoia, Iolanda Vincelli, Roberto Ria, Elena Rivolti, Giuseppe Mele, Alessia Bari, Carla Mazzone, Stefania Badiali, Luigi Marcheselli, Antonio Palumbo, Fortunato Morabito

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing escalating doses of bendamustine and lenalidomide and fixed low doses of dexamethasone (BdL). Fifteen patients were enrolled in phase I study. Maximum tolerated dose was established at dose “level 0”: bendamustine 40 mg/m2 days 1,2; lenalidomide 10 mg days 1–21; d 40 mg days 1,8,15,22 every 28-day cycle, for six cycles. We enrolled 23 patients in the phase II study. BdL combination showed mainly hematological toxicities, fever and infections. Overall response rate was 47%. After median follow up of 22 months, median PFS was 10 months. Two-years OS rate was 65%. BdL combination confirmed to be a promising treatment for patients with relapsed/refractory MM.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - Jul 12 2016

Fingerprint

Multiple Myeloma
Dexamethasone
Therapeutics
Maximum Tolerated Dose
Alkylating Agents
B-Lymphocytes
Fever
Bendamustine Hydrochloride
lenalidomide
Infection
Neoplasms

Keywords

  • bendamustine
  • clinical trial
  • lenalidomide
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. / Pozzi, Samantha; Gentile, Massimo; Sacchi, Stefano; Marcheselli, Raffaella; Corso, Alessandro; Cocito, Federica; Musto, Pellegrino; Guarini, Attilio; Minoia, Carla; Vincelli, Iolanda; Ria, Roberto; Rivolti, Elena; Mele, Giuseppe; Bari, Alessia; Mazzone, Carla; Badiali, Stefania; Marcheselli, Luigi; Palumbo, Antonio; Morabito, Fortunato.

In: Leukemia and Lymphoma, 12.07.2016, p. 1-8.

Research output: Contribution to journalArticle

Pozzi, S, Gentile, M, Sacchi, S, Marcheselli, R, Corso, A, Cocito, F, Musto, P, Guarini, A, Minoia, C, Vincelli, I, Ria, R, Rivolti, E, Mele, G, Bari, A, Mazzone, C, Badiali, S, Marcheselli, L, Palumbo, A & Morabito, F 2016, 'Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study', Leukemia and Lymphoma, pp. 1-8. https://doi.org/10.1080/10428194.2016.1205741
Pozzi, Samantha ; Gentile, Massimo ; Sacchi, Stefano ; Marcheselli, Raffaella ; Corso, Alessandro ; Cocito, Federica ; Musto, Pellegrino ; Guarini, Attilio ; Minoia, Carla ; Vincelli, Iolanda ; Ria, Roberto ; Rivolti, Elena ; Mele, Giuseppe ; Bari, Alessia ; Mazzone, Carla ; Badiali, Stefania ; Marcheselli, Luigi ; Palumbo, Antonio ; Morabito, Fortunato. / Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. In: Leukemia and Lymphoma. 2016 ; pp. 1-8.
@article{6dd97e66eb3449d4b5b33ed4b6d87e73,
title = "Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study",
abstract = "Lenalidomide and dexamethasone are an effective treatment for na{\"i}ve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing escalating doses of bendamustine and lenalidomide and fixed low doses of dexamethasone (BdL). Fifteen patients were enrolled in phase I study. Maximum tolerated dose was established at dose “level 0”: bendamustine 40 mg/m2 days 1,2; lenalidomide 10 mg days 1–21; d 40 mg days 1,8,15,22 every 28-day cycle, for six cycles. We enrolled 23 patients in the phase II study. BdL combination showed mainly hematological toxicities, fever and infections. Overall response rate was 47{\%}. After median follow up of 22 months, median PFS was 10 months. Two-years OS rate was 65{\%}. BdL combination confirmed to be a promising treatment for patients with relapsed/refractory MM.",
keywords = "bendamustine, clinical trial, lenalidomide, Multiple myeloma",
author = "Samantha Pozzi and Massimo Gentile and Stefano Sacchi and Raffaella Marcheselli and Alessandro Corso and Federica Cocito and Pellegrino Musto and Attilio Guarini and Carla Minoia and Iolanda Vincelli and Roberto Ria and Elena Rivolti and Giuseppe Mele and Alessia Bari and Carla Mazzone and Stefania Badiali and Luigi Marcheselli and Antonio Palumbo and Fortunato Morabito",
year = "2016",
month = "7",
day = "12",
doi = "10.1080/10428194.2016.1205741",
language = "English",
pages = "1--8",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study

AU - Pozzi, Samantha

AU - Gentile, Massimo

AU - Sacchi, Stefano

AU - Marcheselli, Raffaella

AU - Corso, Alessandro

AU - Cocito, Federica

AU - Musto, Pellegrino

AU - Guarini, Attilio

AU - Minoia, Carla

AU - Vincelli, Iolanda

AU - Ria, Roberto

AU - Rivolti, Elena

AU - Mele, Giuseppe

AU - Bari, Alessia

AU - Mazzone, Carla

AU - Badiali, Stefania

AU - Marcheselli, Luigi

AU - Palumbo, Antonio

AU - Morabito, Fortunato

PY - 2016/7/12

Y1 - 2016/7/12

N2 - Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing escalating doses of bendamustine and lenalidomide and fixed low doses of dexamethasone (BdL). Fifteen patients were enrolled in phase I study. Maximum tolerated dose was established at dose “level 0”: bendamustine 40 mg/m2 days 1,2; lenalidomide 10 mg days 1–21; d 40 mg days 1,8,15,22 every 28-day cycle, for six cycles. We enrolled 23 patients in the phase II study. BdL combination showed mainly hematological toxicities, fever and infections. Overall response rate was 47%. After median follow up of 22 months, median PFS was 10 months. Two-years OS rate was 65%. BdL combination confirmed to be a promising treatment for patients with relapsed/refractory MM.

AB - Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing escalating doses of bendamustine and lenalidomide and fixed low doses of dexamethasone (BdL). Fifteen patients were enrolled in phase I study. Maximum tolerated dose was established at dose “level 0”: bendamustine 40 mg/m2 days 1,2; lenalidomide 10 mg days 1–21; d 40 mg days 1,8,15,22 every 28-day cycle, for six cycles. We enrolled 23 patients in the phase II study. BdL combination showed mainly hematological toxicities, fever and infections. Overall response rate was 47%. After median follow up of 22 months, median PFS was 10 months. Two-years OS rate was 65%. BdL combination confirmed to be a promising treatment for patients with relapsed/refractory MM.

KW - bendamustine

KW - clinical trial

KW - lenalidomide

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84978952295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978952295&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1205741

DO - 10.1080/10428194.2016.1205741

M3 - Article

SP - 1

EP - 8

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -